When administered to mouse models of atherosclerosis, anti-apoA-1 IgG enhanced atherogenesis, myocardial necrosis and premature death indicating that anti-apoA-1 IgG have the potential to serve as a causative biomarker for CVD [15,16,17]. Here, APOA1 is linked to atherosclerosis.